Source-grounded facts extracted from Atara Biotherapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Kevin G. Sarney was appointed as interim chief financial officer at Atara Biotherapeutics, Inc..
“On June 26, 2026, the Company’s Board of Directors appointed Kevin G. Sarney, Life Science Practice Leader at Charles River CFO, Inc. (“CRCFO”), as interim chief financial officer, effective as of June 26, 2026.”
Yanina Grant-Huerta departed as Chief Accounting Officer at Atara Biotherapeutics, Inc..
“On June 22, 2026, Atara Biotherapeutics, Inc. (the “Company”) notified Yanina Grant-Huerta, the Company’s Chief Accounting Officer, that her employment with the Company would end effective July 17, 2026.”
Brian Cherry was appointed as Class I Director at Atara Biotherapeutics, Inc..
“On June 11, 2026, the Board of Directors (the “ Board ”) of Atara Biotherapeutics, Inc. (the “ Company ”) appointed Brian Cherry to serve as a member of the Board as a Class I director, effective June 11, 2026 (the “ Effective Date ”).”
Atara Biotherapeutics, Inc. shareholders approved Ratification of appointment of independent registered public accounting firm at the 2026-06-09 meeting.
“4. Ratification of appointment of independent registered public accounting firm For Against Abstentions 6,490,311 29,237 1,504 The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Atara Biotherapeutics, Inc. shareholders approved Proposal to approve the first amendment to the Company’s 2024 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 400,000 at the 2026-06-09 meeting.
“3. Proposal to approve the first amendment to the Company’s 2024 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 400,000 For Against Abstain Broker Non-Votes 3,521,021 51,327 3,076 2,945,628 The stockholders approved the amendment to the Company’s 2024 Equity Incentive Plan, as disclosed in the Proxy Statement.”
Atara Biotherapeutics, Inc. shareholders approved Advisory vote to approve on the compensation of the Company's named executive officers at the 2026-06-09 meeting.
“2. Advisory vote to approve on the compensation of the Company’s named executive officers For Against Abstain Broker Non-Votes 3,526,411 44,481 4,532 2,945,628 The stockholders approved, on an advisory basis, the compensation awarded to the Company’s named executive officers, as disclosed in the Proxy Statement.”
Atara Biotherapeutics, Inc. shareholders approved Election of Directors at the 2026-06-09 meeting.
“1. Election of Directors Nominee For Withheld Broker Non-Votes AnhCo Nguyen Ph.D. 3,543,113 32,311 2,945,628 Nachi Subramanian 2,581,435 993,989 2,945,628 Each of the two nominees for director was elected to serve until the 2029 annual meeting of stockholders and until their respective successors are elected.”
Atara Biotherapeutics, Inc. reported first quarter 2026 results: revenue $0.5 million, net income net loss of $4.1 million, EPS ($0.29) basic and diluted loss per share.
“31, 2025. • Net cash used in operating activities was $3.1 million for the first quarter 2026, as compared to $28.1 million in the same period in 2025. • Total revenues were $0.5 million for the first quarter 2026, as compared to $98.1 million for the same period in 2025. The prior ‐ year period reflects a one ‐ time acceleration of revenue recognized upon the”
Atara Biotherapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).
“April 30, 2026, Atara Biotherapeutics, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that t”
Atara Biotherapeutics, Inc. reported the fiscal year ended December 31, 2025 results: revenue $120.8 million, net income $32.7 million, EPS $2.61 per share. Guidance initiated.
“as compared to a net loss of ($12.7) million, or ($1.19) per share, and ($85.4) million, or ($11.41) per share, for the same periods in 2024. ● Commercialization revenues were $120.8 million in 2025 as compared to $128.9 million in 2024. ● Total costs and operating expenses include non-cash stock-based compensation, depreciation and amortization expenses of $1.6”
Atara Biotherapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: net income ($3.4) million, EPS ($0.25) per share. Guidance initiated.
“Atara reported a net loss of ($3.4) million, or ($0.25) per share, and a net income of $32.7 million, or $2.61 per share, for the fourth quarter and fiscal year 2025, respectively”
Atara Biotherapeutics, Inc. issued up to 400,000 shares of the Company's Common Stock of warrant to HCR Molag Fund, L.P. for exercise price is equal to $0.0001 per share.
“the Company issued a warrant to purchase up to 400,000 shares of the Company's Common Stock (the “Warrant”). The exercise price of the Warrant is equal to $0.0001 per share, subject to adjustment as provided therein, and the Warrants will be exercisable immediately and has no expiration date.”
Atara Biotherapeutics, Inc. amended Amendment with HCR Molag Fund, L.P. valued at $9.0 million (effective 2026-02-20).
“On February 20, 2026, Atara Biotherapeutics, Inc., (the “Company”) entered into an Amendment (the “Amendment”) to the Purchase and Sale Agreement dated as of December 20, 2022 (the “Agreement”) with HCR Molag Fund, L.P. (“HCR”). Under the terms of the Amendment, HCR agreed to amend the due date of the one-time of $9.0 million cash payment”
Atara Biotherapeutics, Inc. amended Fourth Amendment with Pierre Fabre Medicament valued at from $40.0 million to $31.0 million (effective 2025-12-30).
“Under the terms of the Amendment, the Company has agreed to reduce the aggregate amount of potential milestone payments payable by Pierre Fabre to the Company upon achieving certain regulatory milestones relating to the approval by the FDA of a BLA for tab-cel from $40.0 million to $31.0 million for the right to receive an additional $15.0 million potential milestone payment from Pierre Fabre to the Company upon achieving a certain commercial milestone.”
Atara Biotherapeutics, Inc. announced a restructuring with charges of $1.3 million (approximately 29% of its current employees).
“to executing on the Company’s strategic priorities. The Company expects to complete the workforce reduction by January 2026. The Company expects to recognize approximately $1.3 million for severance and related benefits for employees laid off under the reduction in force. Approximately fifty percent of these charges are salary continuation payments and wages”
Nachi Subramanian was appointed as Director at Atara Biotherapeutics, Inc..
“the Board approved the appointment of, to be effective immediately following the completion of the Offering, James Huang and Nachi Subramanian to serve as members of the Board”
James Huang was appointed as Director at Atara Biotherapeutics, Inc..
“the Board approved the appointment of, to be effective immediately following the completion of the Offering, James Huang and Nachi Subramanian to serve as members of the Board”
Atara Biotherapeutics, Inc. announced a restructuring with charges of approximately $1.4 million (approximately 30% of its current employees).
“to executing on the Company’s strategic priorities. The Company expects to complete the workforce reduction by August 2025. The Company expects to recognize approximately $1.4 million for severance and related benefits for employees laid off under the reduction in force. These charges are primarily one-time termination benefits and are primarily cash charges.”
Yanina Grant-Huerta was appointed as Chief Accounting Officer at Atara Biotherapeutics, Inc..
“On March 31, 2025, the Company appointed Yanina Grant-Huerta as the Company’s Chief Accounting Officer and principal accounting officer, effective March 31, 2025.”
Eric Hyllengren departed as Chief Financial Officer and Chief Operating Officer at Atara Biotherapeutics, Inc..
“On March 25, 2025, it was agreed that the employment of Eric Hyllengren, the Chief Financial Officer and Chief Operating Officer of Atara Biotherapeutics, Inc. (the “ Company ”), would end effective March 31, 2025.”
Atara Biotherapeutics, Inc. announced a restructuring with charges of approximately $7.5 million in total for severance and related benefits affecting workforce (approximately 50% of its current employees).
“On January 27, 2025, Atara Biotherapeutics, Inc. (the “Company”) announced a reduction in its workforce that will impact approximately 50% of its current employees. The Company expects to substantially complete the workforce reduction by June 2025. The Company expects to recognize approximately $7.5 million in total for severance and related benefits for employees laid off under the reduction in force.”
Atara Biotherapeutics, Inc.: Board approved Third Amended and Restated Bylaws with principal revisions including additional rights to postpone/reschedule special meetings, exclusive use of white proxy card for the Board, meeting conduct rules, stockholder proposal disclosure and procedural requirements, director eligibility req (effective 2024-12-20).
“On December 20, 2024, the Board of Directors (the “ Board ”) of Atara Biotherapeutics, Inc., a Delaware corporation (the “ Company ”), approved the amendment and restatement of the Bylaws of the Company (the “ Third Amended and Restated Bylaws ”).”
Amar Murugan departed as Chief Legal Officer at Atara Biotherapeutics, Inc..
“On November 8, 2024, it was agreed that the employment of Amar Murugan, the Company’s Chief Legal Officer, would end effective November 8, 2024.”
Eric Hyllengren was appointed as Chief Operating Officer at Atara Biotherapeutics, Inc..
“On October 14, 2024, the Board of Directors (the “Board”) of Atara Biotherapeutics, Inc. (the “Company”) appointed Eric Hyllengren to serve as the Company’s Chief Operating Officer, in addition to his role as the Company’s Chief Financial Officer.”
Gregory A. Ciongoli was appointed as member of the Board at Atara Biotherapeutics, Inc..
“On September 3, 2024, Atara Biotherapeutics, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) has appointed, effective as of and contingent upon the Closing Date (as defined below), Mr. Gregory A. Ciongoli to serve as a member of the Board.”
AnhCo Nguyen was appointed as President and Chief Executive Officer at Atara Biotherapeutics, Inc..
“On August 10, 2024, the Board appointed AnhCo Nguyen, Ph.D. as the Company’s President and Chief Executive Officer and a member of the Board, effective September 9, 2024”
Pascal Touchon was appointed as Chairman of the Board at Atara Biotherapeutics, Inc..
“Effective as of the Separation Date, Dr. Touchon will be appointed as Chairman of the Board and will remain a member of the Board.”
Pascal Touchon departed as President and Chief Executive Officer at Atara Biotherapeutics, Inc..
“On August 10, 2024, Pascal Touchon notified the Board of Directors (the “Board”) of the Company of his decision to step down as the Company’s President and Chief Executive Officer, effective as of September 9, 2024”
Atara Biotherapeutics, Inc. reported financial results for first quarter 2024.
“Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.”
Eric Dobmeier departed as Director at Atara Biotherapeutics, Inc..
“On March 26, 2024, Eric Dobmeier, a member of the Board of Directors (the “Board”) of Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), notified the Company of his decision to not stand for re-election to the Board at the Company’s 2024 annual meeting of stockholders (“2024 Annual Meeting”).”
Atara Biotherapeutics, Inc. reported the fourth quarter and full year 2023 results: net income net losses of $60.5 million, or $0.56 per share, and $276.1 million, or $2.61 per share, for the fourth quarter and fisc, EPS $0.56 per share for the fourth quarter and $2.61 per share for the fiscal year 2023.
“Fourth Quarter and Full Year 2023 Financial Results • Cash, cash equivalents and short-term investments as of December 31, 2023 totaled $51.7 million, as compared to $102.4 million as of September 30, 2023 and $242.8 million as of December 31, 2022 • Net cash used in operating activities was $50.4 million and $193.0 million for the fourth quarter and fiscal year 2023, as compared to $56.9 million and $270.4 million in the same periods in 2022 • Atara reported net losses of $60.5 million, or $0.56 per share, and $276.1 million, or $2.61 per share, for the fourth quarter and fiscal year 2023, respectively, as compared to $74.6 million, or $0.72 per share, and $228.3 million, or $2.24 per share, for the same periods in 2022”
Dr. Joshi was terminated as Executive Vice President, Chief Medical Officer at Atara Biotherapeutics, Inc..
“the employment of the Company’s Executive Vice President, Chief Medical Officer would terminate effective as of February 2, 2024”
Atara Biotherapeutics, Inc. entered into Purchase Agreement with certain purchasers valued at approximately $15.0 million (effective 2024-01-08).
“On January 8, 2024, Atara Biotherapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain purchasers (the “Purchasers”) pursuant to which the Company agreed to issue and sell to the Purchasers in a registered direct offering (the “Registered Offering”) pre-funded warrants”
Atara Biotherapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“January 8, 2024, the Company received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s Common Stock closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has been provided a period of 180”
Atara Biotherapeutics, Inc. announced a restructuring with charges of approximately $4.5 million (approximately 25% of its current employees).
“On January 8, 2024, Atara Biotherapeutics, Inc. (the “Company”) announced a reduction in its workforce that will impact approximately 25% of its current employees. The Company expects to substantially complete the workforce reduction by May 2024. The Company expects to recognize approximately $4.5 million in total for severance and related benefits for employees laid off under the reduction in force.”
Manher (AJ) Joshi was terminated as Executive Vice President, Chief Medical Officer at Atara Biotherapeutics, Inc..
“On January 8, 2024, the Company announced that the employment of Manher (AJ) Joshi, the Company’s Executive Vice President, Chief Medical Officer, would terminate effective as of February 2, 2024.”
Atara Biotherapeutics, Inc. reported third quarter ended September 30, 2023 results: net income net loss of $69.8 million, EPS $0.66 per share.
“Atara reported a net loss of $69.8 million, or $0.66 per share for the third quarter 2023”
Atara Biotherapeutics, Inc. announced a restructuring with charges of approximately $7.0 million in total for severance and related benefits (approximately 30% of its current employees).
“On November 1, 2023, the Company announced a reduction in its workforce that will impact approximately 30% of its current employees. The Company expects to substantially complete the workforce reduction by December 31, 2023. The Company expects to recognize approximately $7.0 million in total for severance and related benefits for employees laid off under the reduction in force.”
Atara Biotherapeutics, Inc. amended Amended and Restated Commercialization Agreement with Pierre Fabre Medicament valued at $20 million (effective 2023-10-31).
“On October 31, 2023, Atara Biotherapeutics, Inc. (the “Company”) entered into an Amended and Restated Commercialization Agreement (the “A&R Commercialization Agreement”) with Pierre Fabre Medicament (“Pierre Fabre”), which amends and restates that certain Commercialization Agreement dated October 2, 2021, as amended on September 27, 2022 (the “Original Commercialization Agreement”).”
Atara Biotherapeutics, Inc. reported second quarter ended June 30, 2023 results: net income net loss of $71.1 million, or $0.68 per share for the second quarter 2023.
“Atara reported a net loss of $71.1 million, or $0.68 per share for the second quarter 2023, as compared to net income of $18.5 million, or $0.18 per share for the same period in 2022.”
Charlene Banard departed as Executive Vice President, Chief Technical Officer at Atara Biotherapeutics, Inc..
“On May 8, 2023, Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), announced that Charlene Banard, the Company’s Executive Vice President, Chief Technical Officer, would depart the Company on June 9, 2023.”
Atara Biotherapeutics, Inc. shareholders rejected Approval of an amendment to Company’s Certificate of Incorporation at the 2023-05-31 meeting.
“The stockholders did not approve an amendment of the Company’s Certificate of Incorporation to provide for the exculpation of officers as permitted by Delaware law.”
Atara Biotherapeutics, Inc. shareholders approved Ratification of appointment of independent registered public accounting firm at the 2023-05-31 meeting.
“The stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Atara Biotherapeutics, Inc. shareholders approved Advisory vote to approve on the compensation of the Company’s named executive officers at the 2023-05-31 meeting.
“The stockholders approved, on an advisory basis, the compensation awarded to the Company’s named executive officers, as disclosed in the Proxy Statement.”
Atara Biotherapeutics, Inc. shareholders approved Election of Directors at the 2023-05-31 meeting.
“Each of the three nominees for director was elected to serve until the 2026 annual meeting of stockholders and until their respective successors are elected.”
Beth Seidenberg resigned as Director at Atara Biotherapeutics, Inc..
“On June 1, 2023, Beth Seidenberg, M.D., notified Atara Biotherapeutics, Inc. (the “ Company ”), of her resignation from the Board of Directors of the Company (the “ Board ”), effective immediately.”
Jakob Dupont resigned as Executive Vice President, Global Head of Research and Development at Atara Biotherapeutics, Inc..
“On May 12, 2023, Dr. Dupont resigned from the Company and entered into a consulting agreement with the Company, pursuant to which Dr. Dupont will provide consulting services to the Company through December 31, 2023.”
Atara Biotherapeutics, Inc. reported the first quarter 2023 results: net income net losses of $74.8 million, EPS $0.72 per share.
“Atara reported net losses of $74.8 million, or $0.72 per share for the first quarter 2023”
Charlene Banard departed as Executive Vice President, Chief Technical Officer at Atara Biotherapeutics, Inc..
“Charlene Banard, the Company’s Executive Vice President, Chief Technical Officer, will depart the Company effective as of June 9, 2023”
Jakob Dupont resigned as Executive Vice President, Global Head of Research and Development at Atara Biotherapeutics, Inc..
“Jakob Dupont, M.D., the Company’s Executive Vice President, Global Head of Research and Development, on May 5, 2023, notified the Company of his intention to resign from the Company effective as of May 12, 2023”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.